Abstract 3611
Background
Androgen deprivation therapy (ADT) is standard treatment for rising PSA with/without circulating tumor cells (CTCs) but adverse events (AEs) limit patient acceptance. We report results of SM-88 (D,L-alpha-metyrosine; racemetyrosine [USAN]) in combination with a CYP3A4 inducer, mTOR inhibitor and catalyst that does not lower testosterone (T).
Methods
Phase 2 with a rising PSA (per PCWG3), no disease on imaging and detectable CTCs.
Results
From Sept 2016-April 2019, 35 subjects consented; 23 evaluable (completed >1 cycle); 60.9% were post RT. Mean age 70.6; BMI 28.9; 21.7% black. Mean T rose (319.1 to 346.0 ng/dL p = 0.08) over 12 weeks. Subjects did not report side effects commonly associated with hormone suppression. Assessments of EORTC measured domains sexual health, overall health, and quality of life remained stable, with depression, hot flushes, and enlarged breast reported as “Not at all” (remained at 1). There was no detectable worsening in any domain of EORTC QLQ-C30 or QLQ-PR25. No clinically significant changes were seen in weight, hct, glu, urinary N telopeptide, MAP (in normotensives and hypertensives), heart rate, Ca ++, LDH, bsAlkPhos, triglycerides, albumin, or QTc. NLR decreased at the end of cycle 1 in 75% of those with radiographic and/or PSA progression vs 53% of those who did not. 15/23 (65.2%) subjects reported experiencing an AE. 1 unrelated Grade 3; 18/35 (51.4%) at least possibly related to drug. No AEs were related to T levels. There were no skeletal or cardiovascular events. From initial diagnosis of PSA rise 100% (23/23) remained metastases free. PSA declined (4% 1/23) stabilized (83% 19/23) or rose (13% 3/23). 56.5% (13/23) subjects experienced an improvement in median PSA DT. Median DT time improved from 6.2 to 8.0 months for all subjects completing 3 cycles of therapy. CTCs were > 5 in 100% at baseline. After 12 weeks, there was a 65.3% (-100% to -8.8%) median CTC decrease from baseline (n = 18), with all subjects having CTC counts below baseline and 2 undetectable.
Conclusions
SM-88 may delay the start of HT and be useful when normal T is preferred. QOL was maintained without ADT AEs. Favorable effects on PSA and CTCs kinetics were observed consistent with a favorable treatment effect. Trials to confirm these benefits are planned.
Clinical trial identification
NCT02796898.
Editorial acknowledgement
Legal entity responsible for the study
Tyme Inc.
Funding
Tyme Inc.
Disclosure
G. Del Priore: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment, Officer / Board of Directors: Tyme Inc. G.H. Sokol: Advisory / Consultancy: Tyme Inc. A. Vandell: Full / Part-time employment: Tyme Inc. All other authors have declared no conflicts of interest.
Resources from the same session
2664 - Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy
Presenter: Nicholas Mach
Session: Poster Display session 3
Resources:
Abstract
1285 - Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumors.
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
3808 - GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis
Presenter: Pierpaolo Correale
Session: Poster Display session 3
Resources:
Abstract
5677 - Immune correlates in peripheral blood samples in a preoperative window of opportunity randomized trial of nivolumab with or without tadalafil in resectable squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Larry Harshyne
Session: Poster Display session 3
Resources:
Abstract
4854 - Phase 1 evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies
Presenter: John Powderly
Session: Poster Display session 3
Resources:
Abstract
4344 - Phase 1 Trial of CV301 in Combination with Anti-PD-1 Therapy in Non-squamous NSCLC
Presenter: Arun Rajan
Session: Poster Display session 3
Resources:
Abstract
4555 - Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumors: preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts
Presenter: Henry Conter
Session: Poster Display session 3
Resources:
Abstract
3012 - Excellent CBR and Prolonged PFS in Non-Squamous NSCLC with Oral CA-170, an Inhibitor of VISTA and PD-L1
Presenter: Vivek Radhakrishnan
Session: Poster Display session 3
Resources:
Abstract
2536 - Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers
Presenter: Christophe Le Tourneau
Session: Poster Display session 3
Resources:
Abstract
1845 - Induction of tumor-infiltrating functional CD8 positive cells and PD-L1 expression in esophageal cancer by S-588410
Presenter: Takashi Kojima
Session: Poster Display session 3
Resources:
Abstract